Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.

David M LoebJi Won LeeDaniel A MorgensternYvan SamsonAnne UyttebroeckChuhl Joo LyuAn Van DammeKarsten NysomMargaret E MacyAlexandra P ZorziJulia XiongPetra PollertIngrid JoergYulia VugmeysterMary RuisiHyoung Jin Kang

Published in: Cancer immunology, immunotherapy : CII (2022)

In paediatric patients with refractory/relapsed solid tumours, avelumab monotherapy showed a safety profile consistent with previous adult studies, but clinical benefits were limited.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
hodgkin lymphoma
multiple myeloma
intensive care unit
diffuse large b cell lymphoma
emergency department
open label
combination therapy
randomized controlled trial
young adults